Quick Answer
Xilio Therapeutics, Inc. reported Total Revenue of $43.77 million for fiscal year 2025.
Xilio Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $43.77M +589.9% |
$6.34M | — | — | — | — |
| Revenue (ASC 606) | $43.77M +589.9% |
$6.34M | — | — | — | — |
| Net Income | -$35.04M +39.8% |
-$58.24M +23.8% |
-$76.40M +13.4% |
-$88.22M -16.4% |
-$75.80M -37.3% |
-$55.22M |
| Diluted EPS | -$4.19 +72.5% |
-$15.24 -448.2% |
-$2.78 +13.7% |
-$3.22 +76.2% |
-$13.52 +87.2% |
-$105.42 |
| Total Assets | $154.69M +117.6% |
$71.08M +16.7% |
$60.93M -56.2% |
$139.16M -36.2% |
$218.06M +500.4% |
$36.32M |
| Cash and Equivalents | $137.53M +148.7% |
$55.29M +23.7% |
$44.70M -62.9% |
$120.39M -39.2% |
$198.05M +929.5% |
$19.24M |
| Stockholders Equity | $35.27M +100.4% |
$17.60M -52.2% |
$36.83M -65.1% |
$105.65M -43.0% |
$185.43M +322.6% |
-$83.29M -182.1% |
| R&D Expense | $56.04M +36.0% |
$41.21M -21.0% |
$52.14M -11.9% |
$59.20M +15.7% |
$51.19M +16.6% |
$43.91M |
| Operating Income | -$41.98M +30.7% |
-$60.58M +23.4% |
-$79.13M +11.2% |
-$89.15M -18.8% |
-$75.04M -37.5% |
-$54.56M |
| Shares Outstanding | 4.53M +38.6% |
3.27M -88.2% |
27.61M +0.7% |
27.43M +0.2% |
27.36M +3865.4% |
689,929 |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $19.07M | +742.5% | +135.8% |
| Revenue (ASC 606) | September 30, 2025 | $19.07M | +742.5% | +135.8% |
| Net Income | September 30, 2025 | -$16.29M | -16.2% | -2.8% |
| Diluted EPS | September 30, 2025 | -$0.11 | +50.0% | +31.2% |
| Total Assets | September 30, 2025 | $133.69M | +79.1% | -0.1% |
| Cash and Equivalents | September 30, 2025 | $103.76M | +69.4% | -14.6% |
| Stockholders Equity | September 30, 2025 | -$8.10M | -138.6% | -214.5% |
| R&D Expense | September 30, 2025 | $14.32M | +33.1% | -6.6% |
| Operating Income | September 30, 2025 | -$1.93M | +86.9% | +86.6% |
| Shares Outstanding | September 30, 2025 | 51.83M | +17.9% | +0.0% |
- Xilio Therapeutics, Inc. reported Total Revenue of $43.77 million for fiscal year 2025.
- Xilio Therapeutics, Inc. showed an increase of +589.9% in Total Revenue compared to the prior fiscal year.
- Xilio Therapeutics, Inc. reported Revenue (ASC 606) of $43.77 million for fiscal year 2025.
- Xilio Therapeutics, Inc. showed an increase of +589.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Xilio Therapeutics, Inc. reported Net Income of -$35.04 million for fiscal year 2025.
- Xilio Therapeutics, Inc. showed an increase of +39.8% in Net Income compared to the prior fiscal year.
- Xilio Therapeutics, Inc. reported Diluted EPS of $4.19 per share (loss) for fiscal year 2025.
- Xilio Therapeutics, Inc. showed an increase of +72.5% in Diluted EPS compared to the prior fiscal year.
- Xilio Therapeutics, Inc. reported Total Assets of $154.69 million for fiscal year 2025.
- Xilio Therapeutics, Inc. showed an increase of +117.6% in Total Assets compared to the prior fiscal year.
- Xilio Therapeutics, Inc. reported Cash and Equivalents of $137.53 million for fiscal year 2025.
- Xilio Therapeutics, Inc. showed an increase of +148.7% in Cash and Equivalents compared to the prior fiscal year.
- Xilio Therapeutics, Inc. reported Stockholders Equity of $35.27 million for fiscal year 2025.
- Xilio Therapeutics, Inc. showed an increase of +100.4% in Stockholders Equity compared to the prior fiscal year.
- Xilio Therapeutics, Inc. reported R&D Expense of $56.04 million for fiscal year 2025.
- Xilio Therapeutics, Inc. showed an increase of +36.0% in R&D Expense compared to the prior fiscal year.
- Xilio Therapeutics, Inc. reported Operating Income of -$41.98 million for fiscal year 2025.
- Xilio Therapeutics, Inc. showed an increase of +30.7% in Operating Income compared to the prior fiscal year.
- Xilio Therapeutics, Inc. reported Shares Outstanding of 4.53 million shares for fiscal year 2025.
- Xilio Therapeutics, Inc. showed an increase of +38.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: